Taiki Takaoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taiki Takaoka has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Natsuo Tomita
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
17 shared publications - Akira Torii
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
12 shared publications - Seiya Takano
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
11 shared publications - Nozomi Kita
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
10 shared publications - Akio Hiwatashi
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
9 shared publications Dai Okazaki
Department of Radiology, Nagoya City University Graduate School of Medical Sciences , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
9 shared publications
Latest Publications
- 10 September 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
Dosimetric comparison of automated noncoplanar volumetric-modulated arc therapy and intensity-modulated proton therapy for total scalp irradiation in angiosarcoma of the scalp
Objectives: To compare the dosimetric performance of HyperArc (HA) and intensity-modulated proton therapy (IMPT) for total scalp irradiation (TSI) in patients with angiosarcoma of the scalp (AS). Methods: HyperArc and IMPT treatment plans were retrospectively generated for 27 patients with AS. Prescription doses of 70 and 56 Gy (relative biological effectiveness [RBE]) in 35 fractions were delivered to targets 1 and 2, respectively, using a simultaneous integrated boost technique. HA was optimized to planning target volumes, whereas IMPT employed clinical target volume-based robust optimization. Dose-volume parameters for targets and organs at risk were compared. Beam-on time was evaluated. Results: Both techniques achieved adequate target coverage within dose constraints; HA demonstrated superior dose homogeneity and conformity for target 1, whereas IMPT exhibited greater dose heterogeneity. IMPT significantly reduced low-dose brain exposure (V5 Gy [RBE]) and high-dose exposure to the optic pathway, eyes, lenses, and hippocampus. HA significantly reduced intermediate-to-high brain exposure (V10-V60 Gy [RBE]), mean brain dose, and parotid dose. Moreover, HA achieved a shorter beam-on time. Conclusions: HyperArc and IMPT offer complementary advantages for TSI in AS. HA improves dose homogeneity, reduces intermediate-to-high brain dose, and enhances treatment efficiency; conversely, IMPT better limits low-dose brain exposure and spares critical neural and ocular structures. Modality selection should be individualized according to patient-specific clinical needs. Advances in knowledge: This study presents a direct dosimetric comparison of HA and IMPT for TSI in angiosarcoma of the scalp, demonstrating complementary strengths that may guide individualized modality selection.
- 10 September 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
Dosimetric comparison of automated noncoplanar volumetric-modulated arc therapy and intensity-modulated proton therapy for total scalp irradiation in angiosarcoma of the scalp
Objectives: To compare the dosimetric performance of HyperArc (HA) and intensity-modulated proton therapy (IMPT) for total scalp irradiation (TSI) in patients with angiosarcoma of the scalp (AS). Methods: HyperArc and IMPT treatment plans were retrospectively generated for 27 patients with AS. Prescription doses of 70 and 56 Gy (relative biological effectiveness [RBE]) in 35 fractions were delivered to targets 1 and 2, respectively, using a simultaneous integrated boost technique. HA was optimized to planning target volumes, whereas IMPT employed clinical target volume-based robust optimization. Dose-volume parameters for targets and organs at risk were compared. Beam-on time was evaluated. Results: Both techniques achieved adequate target coverage within dose constraints; HA demonstrated superior dose homogeneity and conformity for target 1, whereas IMPT exhibited greater dose heterogeneity. IMPT significantly reduced low-dose brain exposure (V5 Gy [RBE]) and high-dose exposure to the optic pathway, eyes, lenses, and hippocampus. HA significantly reduced intermediate-to-high brain exposure (V10-V60 Gy [RBE]), mean brain dose, and parotid dose. Moreover, HA achieved a shorter beam-on time. Conclusions: HyperArc and IMPT offer complementary advantages for TSI in AS. HA improves dose homogeneity, reduces intermediate-to-high brain dose, and enhances treatment efficiency; conversely, IMPT better limits low-dose brain exposure and spares critical neural and ocular structures. Modality selection should be individualized according to patient-specific clinical needs. Advances in knowledge: This study presents a direct dosimetric comparison of HA and IMPT for TSI in angiosarcoma of the scalp, demonstrating complementary strengths that may guide individualized modality selection.
- Open Access
- 21 July 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 67 (5) , 796-802
Relationship between rectal bleeding and radiation delivery time in intensity-modulated radiotherapy for localized prostate cancer: a preliminary study
The present study investigated the relationship between late grade ≥ 2 rectal bleeding and radiation delivery time in intensity-modulated radiotherapy (IMRT) for localized prostate cancer. We analyzed patients with localized prostate cancer treated with IMRT at our institution between July 2012 and February 2018, including only those treated with 74.8 Gy in 34 fractions (i.e. a fraction dose of 2.2 Gy). To evaluate the relationship between risk factors and late grade ≥ 2 rectal bleeding, we performed univariate analyses using the Gray test and the Fine-Gray model, and multivariate analysis using the Fine-Gray model. Additionally, propensity score matching was performed to adjust for confounding factors. A total of 142 cases were analyzed. The median follow-up period was 83 months. The 7-year cumulative incidence of late grade ≥ 2 rectal bleeding for the entire cohort was 5.7%. The group with shorter delivery time (≤150 s) had a significantly lower 7-year cumulative incidence of late grade ≥ 2 rectal bleeding compared to the group with longer delivery time (>150 s) (1.5% vs. 9.7%, P = 0.036). Multivariate analysis showed a trend toward an association between longer delivery time and increased late grade ≥ 2 rectal bleeding (hazard ratio 6.1, 95% confidence interval 0.78–48, P = 0.085). In the propensity score-matched cohort, the shorter delivery time group showed a significantly lower incidence of late grade ≥ 2 rectal bleeding (0% vs. 11.1%, P = 0.024). In IMRT for localized prostate cancer, shorter radiation delivery time may reduce the incidence of late grade ≥ 2 rectal bleeding.
- 21 July 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 67 (5) , 796-802
Open AccessRelationship between rectal bleeding and radiation delivery time in intensity-modulated radiotherapy for localized prostate cancer: a preliminary study
The present study investigated the relationship between late grade ≥ 2 rectal bleeding and radiation delivery time in intensity-modulated radiotherapy (IMRT) for localized prostate cancer. We analyzed patients with localized prostate cancer treated with IMRT at our institution between July 2012 and February 2018, including only those treated with 74.8 Gy in 34 fractions (i.e. a fraction dose of 2.2 Gy). To evaluate the relationship between risk factors and late grade ≥ 2 rectal bleeding, we performed univariate analyses using the Gray test and the Fine-Gray model, and multivariate analysis using the Fine-Gray model. Additionally, propensity score matching was performed to adjust for confounding factors. A total of 142 cases were analyzed. The median follow-up period was 83 months. The 7-year cumulative incidence of late grade ≥ 2 rectal bleeding for the entire cohort was 5.7%. The group with shorter delivery time (≤150 s) had a significantly lower 7-year cumulative incidence of late grade ≥ 2 rectal bleeding compared to the group with longer delivery time (>150 s) (1.5% vs. 9.7%, P = 0.036). Multivariate analysis showed a trend toward an association between longer delivery time and increased late grade ≥ 2 rectal bleeding (hazard ratio 6.1, 95% confidence interval 0.78–48, P = 0.085). In the propensity score-matched cohort, the shorter delivery time group showed a significantly lower incidence of late grade ≥ 2 rectal bleeding (0% vs. 11.1%, P = 0.024). In IMRT for localized prostate cancer, shorter radiation delivery time may reduce the incidence of late grade ≥ 2 rectal bleeding.
- Open Access
- 17 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-8
Optimizing safety and efficacy in radiotherapy for external auditory canal cancer
External auditory canal cancer (EACC) is a rare and aggressive malignancy with no established standard treatment. The present study aimed to investigate the efficacy of radiotherapy (RT) for EACC. The data of 42 patients with EACC treated between January 2000 and August 2023 were retrospectively reviewed. Of these, 10 (24%) patients underwent surgery followed by RT (median dose, 60 Gy), whereas 32 (76%) underwent definitive RT (median dose, 66 Gy) and a total of 23 (72%) patients received concurrent chemotherapy with definitive RT. Overall survival (OS), local control (LC), progression-free survival (PFS) and toxicity were examined. The median age of patients was 65 years, and the median follow-up duration was 31.5 months (range: 6–120 months). In all patients, the 3-year OS, LC and PFS rates were 54.8, 65.5 and 49.0%, respectively. The 3-year OS, LC and PFS rates in patients who underwent surgery followed by RT, and those who underwent definitive RT were 90% vs. 42.9% (P=0.008), 100% vs. 53.9% (P=0.01) and 90% vs. 35.9% (P=0.003), respectively. No local recurrence occurred among those who underwent surgery followed by RT, although 50% of these patients had positive or close surgical margins. Grade ≥3 brain toxicities were observed in 3 (7.1%) patients, all of whom had T4 disease and underwent definitive RT with concurrent systemic chemotherapy. In conclusion, compared with definitive RT, surgery followed by RT was associated with favorable outcomes in patients with EACC. A multidisciplinary approach is crucial for optimizing treatment outcomes, especially for patients in the advanced stages of EACC.
- 17 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-8
Open AccessOptimizing safety and efficacy in radiotherapy for external auditory canal cancer
External auditory canal cancer (EACC) is a rare and aggressive malignancy with no established standard treatment. The present study aimed to investigate the efficacy of radiotherapy (RT) for EACC. The data of 42 patients with EACC treated between January 2000 and August 2023 were retrospectively reviewed. Of these, 10 (24%) patients underwent surgery followed by RT (median dose, 60 Gy), whereas 32 (76%) underwent definitive RT (median dose, 66 Gy) and a total of 23 (72%) patients received concurrent chemotherapy with definitive RT. Overall survival (OS), local control (LC), progression-free survival (PFS) and toxicity were examined. The median age of patients was 65 years, and the median follow-up duration was 31.5 months (range: 6–120 months). In all patients, the 3-year OS, LC and PFS rates were 54.8, 65.5 and 49.0%, respectively. The 3-year OS, LC and PFS rates in patients who underwent surgery followed by RT, and those who underwent definitive RT were 90% vs. 42.9% (P=0.008), 100% vs. 53.9% (P=0.01) and 90% vs. 35.9% (P=0.003), respectively. No local recurrence occurred among those who underwent surgery followed by RT, although 50% of these patients had positive or close surgical margins. Grade ≥3 brain toxicities were observed in 3 (7.1%) patients, all of whom had T4 disease and underwent definitive RT with concurrent systemic chemotherapy. In conclusion, compared with definitive RT, surgery followed by RT was associated with favorable outcomes in patients with EACC. A multidisciplinary approach is crucial for optimizing treatment outcomes, especially for patients in the advanced stages of EACC.
- 5 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (5) , 587-594
Impact of intensity-modulated radiotherapy on survival and pulmonary toxicities for localized esophageal squamous cell carcinoma
Objective: Definitive chemoradiotherapy (CRT) is a treatment strategy for localized esophageal squamous cell carcinoma (ESCC). Herein, we aimed to evaluate clinical outcomes of definitive CRT for ESCC. Methods: We reviewed 127 patients who received definitive CRT for localized ESCC at our institution between January 2004 and December 2022. All patients received elective nodal irradiation with concurrent chemotherapy, primarily comprising cisplatin and 5-fluorouracil, during radiotherapy. Seventeen patients (13%) received intensity-modulated radiation therapy (IMRT) only, and 16 patients (13%) were treated with IMRT as a boost. The median total dose was 61.4 Gy. Approximately 80% of the patients had clinical stage III or higher disease. We analyzed overall survival (OS), progression-free survival (PFS), locoregional recurrence rate (LRR), prognostic factors, and adverse events. Results: The median follow-up period was 13 months for all patients and 22 months for survivors. The 2-year OS, PFS, and LRR were 40.4%, 27.1%, and 30.8%, respectively. The overall complete response rate was 40.2%. On multivariate analysis, clinical stage 0–III (non-T4) (P < .001) and the use of IMRT (P = .034) were significantly associated with better OS. Pulmonary toxicity was significantly lower in the IMRT group (P = .049). Conclusions: IMRT for localized ESCC may improve prognosis and reduce pulmonary toxicity.
- 5 February 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (5) , 587-594
Impact of intensity-modulated radiotherapy on survival and pulmonary toxicities for localized esophageal squamous cell carcinoma
Objective: Definitive chemoradiotherapy (CRT) is a treatment strategy for localized esophageal squamous cell carcinoma (ESCC). Herein, we aimed to evaluate clinical outcomes of definitive CRT for ESCC. Methods: We reviewed 127 patients who received definitive CRT for localized ESCC at our institution between January 2004 and December 2022. All patients received elective nodal irradiation with concurrent chemotherapy, primarily comprising cisplatin and 5-fluorouracil, during radiotherapy. Seventeen patients (13%) received intensity-modulated radiation therapy (IMRT) only, and 16 patients (13%) were treated with IMRT as a boost. The median total dose was 61.4 Gy. Approximately 80% of the patients had clinical stage III or higher disease. We analyzed overall survival (OS), progression-free survival (PFS), locoregional recurrence rate (LRR), prognostic factors, and adverse events. Results: The median follow-up period was 13 months for all patients and 22 months for survivors. The 2-year OS, PFS, and LRR were 40.4%, 27.1%, and 30.8%, respectively. The overall complete response rate was 40.2%. On multivariate analysis, clinical stage 0–III (non-T4) (P < .001) and the use of IMRT (P = .034) were significantly associated with better OS. Pulmonary toxicity was significantly lower in the IMRT group (P = .049). Conclusions: IMRT for localized ESCC may improve prognosis and reduce pulmonary toxicity.
- Open Access
- 18 December 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (24) , e70204
Impact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma
Background: Thymoma is a rare thymic epithelial tumor, and its prognostic factors remain not fully elucidated. This study aimed to identify simple, practical preoperative predictors of prognosis, focusing on tumor dimensions assessed by computed tomography (CT). Methods: We retrospectively analyzed 181 patients who underwent complete or partial resection for thymoma between 2004 and 2022. Tumor size was assessed by measuring the maximum transverse and craniocaudal dimensions on preoperative CT. Freedom from recurrence (FFR) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional hazards models were constructed: Model A included only preoperative variables, while Model B additionally incorporated postoperative factors (e.g., TNM stage classification and histology). Results: During a median follow‐up of 96 months, the 5‐ and 10‐year FFR rates were 78.4% and 71.4%, and the corresponding OS rates were 96.5% and 87.3%, respectively. In multivariate analysis, TNM stage classification and preoperative steroid pulse therapy were significantly associated with FFR, whereas no variables were significantly associated with OS. Model A demonstrated good discriminatory ability ( C ‐index = 0.839), which improved only modestly after including postoperative factors in Model B ( C ‐index = 0.867). In the steroid‐excluded cohort ( N = 148), the craniocaudal tumor dimension emerged as a significant predictor of FFR ( p = 0.027). Conclusions: The craniocaudal tumor dimension measured on preoperative CT was consistently associated with recurrence and may reflect prognostic information embedded within the pathological TNM classification. This easily measurable parameter could complement TNM‐based evaluation in preoperative risk assessment and surgical decision‐making for thymoma.
- 18 December 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (24) , e70204
Open AccessImpact of Craniocaudal Tumor Dimension and the Ninth Edition of the TNM Stage Classification on Prognosis in Resected Thymoma
Background: Thymoma is a rare thymic epithelial tumor, and its prognostic factors remain not fully elucidated. This study aimed to identify simple, practical preoperative predictors of prognosis, focusing on tumor dimensions assessed by computed tomography (CT). Methods: We retrospectively analyzed 181 patients who underwent complete or partial resection for thymoma between 2004 and 2022. Tumor size was assessed by measuring the maximum transverse and craniocaudal dimensions on preoperative CT. Freedom from recurrence (FFR) and overall survival (OS) were estimated using the Kaplan–Meier method. Cox proportional hazards models were constructed: Model A included only preoperative variables, while Model B additionally incorporated postoperative factors (e.g., TNM stage classification and histology). Results: During a median follow‐up of 96 months, the 5‐ and 10‐year FFR rates were 78.4% and 71.4%, and the corresponding OS rates were 96.5% and 87.3%, respectively. In multivariate analysis, TNM stage classification and preoperative steroid pulse therapy were significantly associated with FFR, whereas no variables were significantly associated with OS. Model A demonstrated good discriminatory ability ( C ‐index = 0.839), which improved only modestly after including postoperative factors in Model B ( C ‐index = 0.867). In the steroid‐excluded cohort ( N = 148), the craniocaudal tumor dimension emerged as a significant predictor of FFR ( p = 0.027). Conclusions: The craniocaudal tumor dimension measured on preoperative CT was consistently associated with recurrence and may reflect prognostic information embedded within the pathological TNM classification. This easily measurable parameter could complement TNM‐based evaluation in preoperative risk assessment and surgical decision‐making for thymoma.
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1650-1659
Re-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer
Background: Salvage treatment for local recurrence of non-small cell lung cancer (NSCLC) after stereotactic body radiotherapy (SBRT) remains unestablished. We investigated the safety and efficacy of a second SBRT course for in-field local recurrence of NSCLC after definitive SBRT. Methods: This study included 35 patients with NSCLC who received a second SBRT course between July 2004 and August 2021. The median interval between the first and second SBRT was 24 months (range, 6–81 months). The median prescription dose was 60 Gy in eight fractions (range, 48–66 Gy) for the second SBRT. Overall survival (OS), local control (LC), progression-free survival (PFS), and toxicity after a second SBRT were assessed. Results: The median follow-up period was 29 months (range, 3–124 months). The three-year OS, LC, and PFS rates were 50%, 47%, and 34% for all 35 patients and 72% vs. 21%, 85% vs. 34%, and 62% vs. 9% in the adenocarcinoma and squamous cell carcinoma groups, respectively (P=0.04, 0.01, and 0.003, respectively). Four patients demonstrated no further recurrence for more than five years after the second SBRT. Radiation pneumonitis after the second SBRT was grade 2 in three (8.5%) patients, rib fractures occurred in nine (25.7%) patients, and no patient developed grade 3 or higher toxicity. Conclusions: Re-irradiation with SBRT was safe and can be a salvage treatment option for in-field local recurrence of NSCLC, especially adenocarcinoma, after definitive SBRT.
- 1 May 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (5) , 1650-1659
Open AccessRe-irradiation for local recurrence after definitive stereotactic body radiotherapy for early-stage non-small cell lung cancer
Background: Salvage treatment for local recurrence of non-small cell lung cancer (NSCLC) after stereotactic body radiotherapy (SBRT) remains unestablished. We investigated the safety and efficacy of a second SBRT course for in-field local recurrence of NSCLC after definitive SBRT. Methods: This study included 35 patients with NSCLC who received a second SBRT course between July 2004 and August 2021. The median interval between the first and second SBRT was 24 months (range, 6–81 months). The median prescription dose was 60 Gy in eight fractions (range, 48–66 Gy) for the second SBRT. Overall survival (OS), local control (LC), progression-free survival (PFS), and toxicity after a second SBRT were assessed. Results: The median follow-up period was 29 months (range, 3–124 months). The three-year OS, LC, and PFS rates were 50%, 47%, and 34% for all 35 patients and 72% vs. 21%, 85% vs. 34%, and 62% vs. 9% in the adenocarcinoma and squamous cell carcinoma groups, respectively (P=0.04, 0.01, and 0.003, respectively). Four patients demonstrated no further recurrence for more than five years after the second SBRT. Radiation pneumonitis after the second SBRT was grade 2 in three (8.5%) patients, rib fractures occurred in nine (25.7%) patients, and no patient developed grade 3 or higher toxicity. Conclusions: Re-irradiation with SBRT was safe and can be a salvage treatment option for in-field local recurrence of NSCLC, especially adenocarcinoma, after definitive SBRT.
- Open Access
Clinical Outcomes and Prognostic Factors for Extramammary Paget’s Disease Treated with Radiation Therapy: A Multi-Institutional Observational Study
Background: Extramammary Paget’s disease (EMPD) is a rare cutaneous carcinoma that typically affects the elderly and is frequently observed in genital and perianal regions. We analyzed the outcomes and prognostic factors for EMPD after radiation therapy (RT). Methods: We analyzed data from 81 patients with non-metastatic EMPD who received either RT alone or in combination with surgery and/or chemotherapy. The median radiation dose was 56 Gy in 28 fractions. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan–Meier method. Multivariate analyses were performed using the Cox proportional hazards model. Late adverse events were evaluated by NCI-CTCAE version 5.0. Results: The median age was 78 years, and the median follow-up period was 36 months. The three-year LC, PFS, and OS rates were 75%, 52%, and 80%, respectively. Multivariate analyses identified the presence of lymph node (LN) metastasis, the absence of surgery, and the omission of elective nodal irradiation (i.e., local irradiation only) as significant factors for unfavorable LC (p = 0.01, 0.02, and 0.006) and PFS (p = 0.001, 0.04, and 0.03). LN metastasis was also a significant factor for unfavorable OS (p = 0.005). One patient developed grade 2 skin infection, and another developed grade 3 lymphedema; no grade 4 or higher toxicity was observed. Conclusions: The present results revealed prognostic factors for EMPD after RT and suggest that the absence of surgery and omission of elective nodal irradiation worsened outcomes. A prospective study is needed to establish an optimal treatment strategy for this rare malignancy, which is common in the elderly.
Open AccessClinical Outcomes and Prognostic Factors for Extramammary Paget’s Disease Treated with Radiation Therapy: A Multi-Institutional Observational Study
Background: Extramammary Paget’s disease (EMPD) is a rare cutaneous carcinoma that typically affects the elderly and is frequently observed in genital and perianal regions. We analyzed the outcomes and prognostic factors for EMPD after radiation therapy (RT). Methods: We analyzed data from 81 patients with non-metastatic EMPD who received either RT alone or in combination with surgery and/or chemotherapy. The median radiation dose was 56 Gy in 28 fractions. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were calculated using the Kaplan–Meier method. Multivariate analyses were performed using the Cox proportional hazards model. Late adverse events were evaluated by NCI-CTCAE version 5.0. Results: The median age was 78 years, and the median follow-up period was 36 months. The three-year LC, PFS, and OS rates were 75%, 52%, and 80%, respectively. Multivariate analyses identified the presence of lymph node (LN) metastasis, the absence of surgery, and the omission of elective nodal irradiation (i.e., local irradiation only) as significant factors for unfavorable LC (p = 0.01, 0.02, and 0.006) and PFS (p = 0.001, 0.04, and 0.03). LN metastasis was also a significant factor for unfavorable OS (p = 0.005). One patient developed grade 2 skin infection, and another developed grade 3 lymphedema; no grade 4 or higher toxicity was observed. Conclusions: The present results revealed prognostic factors for EMPD after RT and suggest that the absence of surgery and omission of elective nodal irradiation worsened outcomes. A prospective study is needed to establish an optimal treatment strategy for this rare malignancy, which is common in the elderly.
- 6 September 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (1) , 59-66
Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery
Objective: There is no consensus on the optimal treatment for patients with locoregional recurrence of esophageal cancer after surgery. The objective of this study was to investigate the outcomes and prognostic factors associated with salvage radiotherapy in patients with locoregional recurrence of esophageal cancer after surgery. Methods: We reviewed 80 patients with locoregional recurrence of esophageal cancer after surgery who were treated with radiotherapy. The median dose was 60 Gy, and 29 patients (36%) received elective nodal irradiation. Fifty-three patients (66%) received concurrent chemotherapy (mostly 5-fluorouracil and cisplatin) during radiotherapy. Overall survival, progression-free survival and in-field recurrence rate were assessed. Results: The median follow-up period was 17 months. Two-year overall survival, progression-free survival and in-field recurrence rate were 50.3%, 23.5% and 41.3%, respectively. On multivariate analysis, a maximum diameter of locoregional recurrence lesions 14 months was associated with higher PFS (P = 0.003). Late grade 3 toxicities occurred in three patients (3.8%). No grade 4 or higher toxicity was observed. Conclusions: Salvage radiotherapy demonstrated efficacy in achieving in-field control with acceptable toxicity. However, the high rate of out-of-field metastases led to poor progression-free survival and overall survival, particularly in cases involving large lesions and a short disease-free interval. A prospective study is warranted to establish a treatment strategy, particularly considering the combined use of effective anti-cancer drugs.
- 6 September 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (1) , 59-66
Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery
Objective: There is no consensus on the optimal treatment for patients with locoregional recurrence of esophageal cancer after surgery. The objective of this study was to investigate the outcomes and prognostic factors associated with salvage radiotherapy in patients with locoregional recurrence of esophageal cancer after surgery. Methods: We reviewed 80 patients with locoregional recurrence of esophageal cancer after surgery who were treated with radiotherapy. The median dose was 60 Gy, and 29 patients (36%) received elective nodal irradiation. Fifty-three patients (66%) received concurrent chemotherapy (mostly 5-fluorouracil and cisplatin) during radiotherapy. Overall survival, progression-free survival and in-field recurrence rate were assessed. Results: The median follow-up period was 17 months. Two-year overall survival, progression-free survival and in-field recurrence rate were 50.3%, 23.5% and 41.3%, respectively. On multivariate analysis, a maximum diameter of locoregional recurrence lesions 14 months was associated with higher PFS (P = 0.003). Late grade 3 toxicities occurred in three patients (3.8%). No grade 4 or higher toxicity was observed. Conclusions: Salvage radiotherapy demonstrated efficacy in achieving in-field control with acceptable toxicity. However, the high rate of out-of-field metastases led to poor progression-free survival and overall survival, particularly in cases involving large lesions and a short disease-free interval. A prospective study is warranted to establish a treatment strategy, particularly considering the combined use of effective anti-cancer drugs.
- Open Access
- 14 August 2024
- Published by MDPI AG in Preprints.org
Fractionated Stereotactic Intensity-Modulated Radiotherapy for Large Brain Metastases: Comprehensive Analyses of Dose-Volume Predictors of Radiation-Induced Brain Necrosis
Background: Dosimetric predictors of brain necrosis (BN) have not yet been established for fractionated stereotactic radiotherapy (SRT). Methods: Multivariate logistic models were developed for comprehensive analyses of dosimetric predictors in patients who received first-line fractionated SRT for brain metastases (BMs). The normal brain volume receiving a xx Gy biological dose in 2 Gy fractions (VxxGyE) was calculated from the retrieved dose-volume parameters. Results: Three-fraction SRT was delivered to 34 patients with 74 BMs (mean target volume, 4.3 cc), 5-fraction SRT to 58 with 106 BMs (15.4 cc), and 10-fraction SRT to 20 with 35 BMs (25.9 cc) according to protocols depending on the target volume (p 20 cc (p <0.05). Conclusion: In 5- or 10-fraction SRT, at least V55GyE ≤30 cc or V60GyE ≤20 cc should be maintained to lower the risk of BN.
- 14 August 2024
- Published by MDPI AG in Preprints.org
Open AccessFractionated Stereotactic Intensity-Modulated Radiotherapy for Large Brain Metastases: Comprehensive Analyses of Dose-Volume Predictors of Radiation-Induced Brain Necrosis
Background: Dosimetric predictors of brain necrosis (BN) have not yet been established for fractionated stereotactic radiotherapy (SRT). Methods: Multivariate logistic models were developed for comprehensive analyses of dosimetric predictors in patients who received first-line fractionated SRT for brain metastases (BMs). The normal brain volume receiving a xx Gy biological dose in 2 Gy fractions (VxxGyE) was calculated from the retrieved dose-volume parameters. Results: Three-fraction SRT was delivered to 34 patients with 74 BMs (mean target volume, 4.3 cc), 5-fraction SRT to 58 with 106 BMs (15.4 cc), and 10-fraction SRT to 20 with 35 BMs (25.9 cc) according to protocols depending on the target volume (p 20 cc (p <0.05). Conclusion: In 5- or 10-fraction SRT, at least V55GyE ≤30 cc or V60GyE ≤20 cc should be maintained to lower the risk of BN.
- Open Access
- 28 April 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 30, 100583
Comparing different boost concepts and beam configurations for proton therapy of pancreatic cancer
- 28 April 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 30, 100583
Open AccessComparing different boost concepts and beam configurations for proton therapy of pancreatic cancer